Description
Indication & Scope
Redemplo® is an RNA interference (RNAi) therapy indicated, as an adjunct to diet, for reducing triglyceride levels in adult patients with familial chylomicronemia syndrome (FCS).Plozasiran Sodium is a GalNAc-conjugated siRNA that targets APOC3 mRNA, reducing apolipoprotein C-III production and promoting triglyceride clearance.
Mechanism:
Plozasiran Sodium selectively degrades hepatic APOC3 mRNA through RNA interference, decreasing apolipoprotein C-III synthesis and accelerating triglyceride metabolism.
Drug class:
GalNAc-conjugated small interfering RNA (siRNA).
Clinical use:
Reduction of triglyceride levels in adult patients with familial chylomicronemia syndrome (FCS).
| Generic Name | Plozasiran Sodium Injection |
| Brand Name | Redemplo® |
| Ingredient | Plozasiran Sodium |
| Dosage Form | Injection |
| Package | 25 mg/0.5 mL prefilled syringe |
| Conditions Treated | Familial chylomicronemia syndrome (FCS) |
| Taboos | Hypersensitivity to Plozasiran Sodium or any component of the product |
| Place of origin | United States |
| Prescription type | Prescription Drug (Rx) |
| Storage Conditions | Store refrigerated at 2°C–8°C. Do not freeze. Protect from light. |
| Manufacturer | Arrowhead Pharmaceuticals, Inc. |
| Registration Authority | National Medical Products Administration (NMPA), China |
| Approval number | H20260007 |
| Date of Revision | 2026 |
| Shelf Life | 24 months |
How to use ?
Recommended Dose: The recommended dose is 25 mg (0.5 mL) administered by subcutaneous injection once every 3 months.
Time: Administer once every three months according to the prescribed dosing schedule.
Instructions for use: Inject subcutaneously into the abdomen, thigh, or upper arm. Rotate injection sites. The first injection should be administered under healthcare professional supervision. Continue a strict low-fat diet during treatment.
Interaction: Plozasiran Sodium is not metabolized by CYP450 enzymes and has minimal potential for drug-drug interactions. It may be used together with conventional lipid-lowering therapies.
Side effects: Common adverse reactions include injection-site reactions, pain, erythema, pruritus, fatigue, and headache.
Important Notice
This product should be administered only by qualified healthcare professionals in accordance with the approved prescribing information and local clinical guidelines. Dosage and administration may vary depending on patient condition, indicatiaon, and regional regulatory requirements.
Packaging & Shipping
Packaging
Original manufacturer’s packaging with secure export carton. Customized export packaging is available upon request.
Shipping Methods
Express Courier (EMS, DHL, FedEx, UPS), Air Freight, and Sea Freight. Cold-chain transportation is available for products requiring temperature-controlled logistics.
Export Support
Certificate of Analysis
GMP Certificate
Commercial Invoice
Packing List & CPP
Cold Chain Logistics
Customs Documentation
Scientific and regulatory sources
FAQ
What type of compound is plozasiran‑sodium?
It is an siRNA‑based oligonucleotide molecule.
How does plozasiran‑sodium exert pharmacological effects?
It down‑regulates target‑gene expression to cut down triglyceride synthesis.
What is the recommended dose based on the active ingredient?
25 mg of plozasiran‑sodium by subcutaneous injection once every three months.
What is its approved indication?
Reduce triglycerides for adult patients with familial chylomicronemia syndrome (FCS) as an adjunct to diet.
Redemplo® | Plozasiran Sodium | FCS Treatment | DengYueRX
INN: Plozasiran Sodium
Indications: Familial chylomicronemia syndrome (FCS)
Dosage Form: Injection
Strength: 25 mg/0.5 mL
